ACEIs, ARBs, Ibuprofen linked to COVID-19: The other side of the broken mirror

Abstract

This article discusses from a pharmacological point of view, the points of weakness in a correspondence published at the Lancet Respiratory Medicine that has suggested a hypothesis relating ACEIs, ARBs and ibuprofen to be associated with a higher risk for COVID-19 infection and complications. This article also explains some unfortunate mistakes that have been made by some who have adopted this hypothesis and decided to unwisely recommend against these important drugs.

Breakthrough: Ibuprofen/nitazoxanide/azithromycin: a battle changer personalized COVID-19 telemedicine five days protocol

“…This suggestion is contradicting all the current practical approach adopted world-wide that avoided NSAIDs and preferred paracetamol. Noteworthy, the author has fully explained the incident that led to the world to avoid use of ibuprofen 7 and he's also recommended against the routine use of steroids in COVID-19 but suggested to be administered for patients with late acute respiratory syndrome 2 and most recently this suggestion has been proved clinically valid 8…”